Interorganelle competition for linoleic acid underlies steatotic liver pathology
Chuanhai ZhangiD, Dengbao YangiD, Hiroyuki SuzukiiD, Goncalo DiasdoVale, Jingxuan CheniD, Amogh VaidyaiD, Kamran MelikoviD, Alexandra E. Swisher, Jingjing WangiD, Mengchen YeiD, Jin Rong ZhouiD, Qiyu Zeng, Meijuan BaiiD, Mei-Jung Lin, Jeon LeeiD, Hao ZhuiD, Daniel J. SiegwartiD, Yujin HoshidaiD, Jeffrey G. McDonaldiD, Xing ZengiD
Abstract
Lipid droplets (LDs) are traditionally viewed as protective organelles that sequester potentially cytotoxic lipids. However, whether and how LD biogenesis in pathological contexts actively rewires interorganelle lipid homeostasis to drive organelle dysfunction and disease progression remains unexplored. Here, we identify the adipocyte-enriched protein calsyntenin 3{beta} (CLSTN3B) as a critical promoter of metabolic dysfunction-associated steatotic liver disease (MASLD). CLSTN3B, an ER-LD contact protein previously shown to support LD maturation in adipocytes, is robustly induced in mouse hepatocytes by peroxisome proliferator-activated receptor {gamma} (PPAR{gamma}) in response to dietary caloric overload. CLSTN3B drives LD biogenesis and neutral lipid storage by stabilizing hemifusion-like ER-LD membrane bridges via its arginine-rich segment. These bridges preferentially recruit cone-shaped linoleoylated phosphatidic acid (PA), diverting linoleic acid (LA) into triacylglycerides (TAGs) rather than mitochondrial cardiolipin (CL), leading to disrupted cristae architecture, deficient ETC supercomplex assembly, elevated electron leak, and oxidative stress. Hepatocyte-specific CLSTN3B deletion impairs LD formation, reduces TAG accumulation, enhances fatty acid oxidation, restores CL maturation, and mitigates oxidative stress, collectively attenuating MASLD progression. Consistently, hepatic CLSTN3B expression correlates with fibrosis severity and progression in human MASLD. These findings position LDs as active regulators of interorganelle lipid partitioning and establish CLSTN3B as a key determinant of mitochondrial vulnerability, providing a general framework for how dysregulated organelle interfaces shape disease.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Hepatocyte-specific CLSTN3B ablation impairs lipid droplet maturation and alleviates diet-induced steatohepatitis in mice
Chuanhai Zhang, Dengbao Yang, … Xing Zeng·bioRxiv·May 20, 2025
- CLSTN3B enhances adipocyte lipid droplet structure and function via endoplasmic reticulum contact
Chuanhai Zhang, Mengchen Ye, … Xing Zeng·Nature CommunicationsPeer-reviewed·Nov 2, 2024
- Spatially resolved rewiring of mitochondria-lipid droplet interactions in hepatic lipid homeostasis
Sun Woo Sophie Kang, Lauryn A. Brown, … Natalie Porat‐Shliom·Nature MetabolismPeer-reviewed·Mar 23, 2026
- Cardiolipin deficiency disrupts electron transport chain and drives steatohepatitis
Marisa J. Brothwell, Guoshen Cao, … Katsuhiko Funai·eLifePeer-reviewed·Sep 2, 2026
- A Host Enzyme Reduces Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) by Inactivating Intestinal Lipopolysaccharide
Zhiyan Wang, Nore Ojogun, … Mingfang Lu·eLifePeer-reviewed·Oct 14, 2024
- Inhibition of p107 alleviates liver steatosis by reducing de novo fatty acid synthesis.
Juan Cuñarro, Marta Varela Miguens, … Sulay A. Tovar·bioRxiv·Apr 16, 2026